Unknown

Dataset Information

Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer.


ABSTRACT: Antibodies against inhibitory immune checkpoint molecules (ICPMs), referred to as immune checkpoint inhibitors (ICIs), have gained a prominent place in cancer therapy. Several ICIs in clinical use have been engineered to be devoid of effector functions because of the fear that ICIs with preserved effector functions could deplete immune cells, thereby curtailing antitumor immune responses. ICPM ligands (ICPMLs), however, are often overexpressed on a sizeable fraction of tumor cells of many tumor types and these tumor cells display an aggressive phenotype with changes typical of tumor cells undergoing an epithelial-mesenchymal transition. Moreover, immune cells expressing ICPMLs are often endowed with immunosuppressive or immune-deviated functionalities. Taken together, these observations su

SUBMITTER: Marcucci F 

PROVIDER: S-EPMC8069236 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature